ABBOTT LABORATORIES
Company Stats
- Market Cap
- $171.0B
- as of Sep 30, 2026
- Shares Outstanding
- 1.7B
- Free Float
- 95.7%
Income Statement
- Revenue
- $44.3B
- Operating Income
- $8.1B
- Net Income
- $6.5B
- EBITDA
- $9.5B
- Revenue Growth, 3Y
- 0.5%
- FCF Margin, 3Y Avg
- 14.8%
- FCF Margin, Worst Year
- 12.6%
Cash Flow
- Free Cash Flow
- $7.4B
- FCF Yield
- 4.3%
- Owner FCF Yield
- 3.9%
Balance Sheet
- Cash & Equivalents
- $8.5B
Returns & Capital
- Dividends Paid
- $4.1B
- Dividend Yield
- 2.4%
- Dividend Payout, 3Y Avg
- 51.3%
- Share Repurchases
- $893.0M
- Buyback Yield, 3Y Avg
- 0.7%
- SBC, 3Y Avg
- $660.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $44.3B | $7.4B | 16.7% |
| FY2024 | $42.0B | $6.4B | 15.1% |
| FY2023 | $40.1B | $5.1B | 12.6% |
| FY2022 | $43.7B | $7.8B | 17.9% |
| FY2021 | $43.1B | $8.6B | 20.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Abbott Plans Spin of Nutrition Unit With $8.5 Billion in Annual Sales
Stronger demand supports expansion as pricing diverges
Institutions Rotate Into Semis, Retail, and Industrials